Pair Name	Sclareol, Doxorubicin
Partner Name	Doxorubicin
Disease Info	[ICD-11: 2C60]	Breast cancer		Investigative
In Vitro Model	MCF-7	Invasive breast carcinoma of no special type	Homo sapiens (Human)	CVCL_0031
	4T1	Malignant neoplasms of the mouse mammary gland	Mus musculus (Mouse)	CVCL_0125
Result	The developed SLN efficiently encapsulate DOX and SC and show good potential as an alternative for cancer treatment.

Pair Name	Sclareol, Cisplatin
Partner Name	Cisplatin
Disease Info	[ICD-11: 2C25]	Lung cancer		Investigative
Gene Regulation	Down-regulation	Expression	AKT1	hsa207
	Down-regulation	Expression	ERCC1	hsa2067
	Down-regulation	Expression	JUN	hsa3725
	Down-regulation	Expression	MAPK8	hsa5599
	Down-regulation	Expression	SNAI1	hsa6615
In Vitro Model	A-549	Lung adenocarcinoma	Homo sapiens (Human)	CVCL_0023
In Vivo Model	These mice were subcutaneously injected with A549 cells (6×10⁶ cells in 100 μL of PBS).
Result	Sclareol has potential as an adjuvant for the treatment in NSCLC patients with cisplatin resistance.

Pair Name	Sclareol, Doxorubicin
Partner Name	Doxorubicin
Disease Info	[ICD-11: 2C60]	Breast cancer		Investigative
In Vitro Model	MDA-MB-231	Breast adenocarcinoma	Homo sapiens (Human)	CVCL_0062
	4T1	Malignant neoplasms of the mouse mammary gland	Mus musculus (Mouse)	CVCL_0125
In Vivo Model	4T1 (2.5×10⁶) tumour cells were subcutaneously injected into the right thigh of female BALB/c mice (5 weeks old, around 20 g).
Result	This work shows that SC and DOX present synergistic anticancer activity for breast cancer treatment whereas NLC-DOX-SC was a feasible alternative to attain the benefits posed by DOX:SC combination but with none to fewer side effects.